Advertisement
Advertisement
U.S. Markets open in 1 hr 21 mins
Advertisement
Advertisement
Advertisement
Advertisement

Arch Therapeutics, Inc. (ARTH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0391-0.0019 (-4.63%)
At close: 03:58PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0410
Open0.0450
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0350 - 0.0450
52 Week Range0.0350 - 0.1400
Volume611,366
Avg. Volume204,220
Market Cap9.273M
Beta (5Y Monthly)-0.40
PE Ratio (TTM)N/A
EPS (TTM)-0.0280
Earnings DateDec 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing

    Uplisting is the Next Significant StepFRAMINGHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it completed a private placement through the issuance of senior secured convertible notes (the “Notes”) with gross proceeds of approximately $3.5 million from select institutional and accredited individual investors (the “Financing”), b

  • GlobeNewswire

    Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel

    Initial A4100 code being deployed and application for specific HCPCS product code to be submitted in the second calendar quarterFRAMINGHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided an update regarding its reimbursement strategy for the use of AC5® Advanced Wound System (“AC5”), specifically regarding its use in doctor’s offices and

  • GlobeNewswire

    Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring

    World-renowned Wound Care Leaders, Terry Treadwell, MD, FACS and Brock Liden, DPM, Shared Insights on Success with AC5® Advanced Wound SystemFRAMINGHAM, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, announced today that the third interview in the Experts in Wound Care Program, a series of interviews with key opinion leaders dedicated to advancing wound

Advertisement
Advertisement